Brief: VBL Therapeutics and Nanocarrier sign exclusive agreement for VB-111 in Japan

Nano Holdings

06/11/2017 12:00

Nov 6 (Reuters) - Nanocarrier Co Ltd  4571.T  
    * VBL Therapeutics and Nanocarrier Co., ltd. sign exclusive 
agreement for VB-111 in Japan 
    * Vascular Biogenics Ltd - Nanocarrier receives exclusive 
rights 
to VB-111 in Japan, VBLT retains rights in rest of world 
    * Vascular - pursuant to agreement, VBLT to supply 
Nanocarrier 
with VB-111 
    * Vascular - Nanocarrier will be responsible for all 
regulatory, 
other clinical activities necessary for commercialization of 
VB-111 in Japan 
    * Vascular - VBLT receives up-front payment of $15 million & 
is 
entitled to receive greater than $100 million in development & 
commercial milestone payments 
    * Vascular Biogenics Ltd - VBLT will also receive tiered 
royalties on net sales in high-teens 
    * Vascular Biogenics Ltd - other terms of agreement not 
disclosed 
 
Source text for Eikon:  ID:nGNXOGQEJa  
Further company coverage:  4571.T  
 
 ((Bangalore.newsroom@thomsonreuters.com;))